In the ASCEND-1, ASCEND-2, and ASCEND-5 trials, ceritinib was evaluated in ALK+ NSCLC patients with prior platinum-based chemotherapy and/or crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.